Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Devdiscourse1h
Novo Nordisk's CagriSema Trial Results Fall Short, Market Reacts
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...
Investor's Business Daily on MSN1h
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
360Dx1h
Neurology Blood Tests Primed to Improve Diagnosis, Management of Patients in Alzheimer's and Beyond
Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.